The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1423
August 19, 2013
View Complete Issue         Table of Contents 2019 
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
August 19, 2013 (Issue: 1423)
The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab (Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or Still’s disease) in children ≥2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
Article code: 1423a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.